[1] Christensen JH, Rittig S. Familial neurohypophyseal diabetes insipidus--an update. Semin Nephrol 2006; 26: 209-223.
[2] Hagiwara D, Grinevich V, Arima H. A novel mechanism of autophagy-associated cell death of vasopressin neurons in familial neurohypophysial diabetes insipidus. Cell Tissue Res 2019; 375: 259-266.
[3] Rigoli L, Bramanti P, Di Bella C, et al. Genetic and clinical aspects of Wolfram syndrome 1, a severe neurodegenerative disease. Pediatr Res 2018; 83: 921929.
[4] Pallotta MT, Tascini G, Crispoldi R, et al. Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives. J Transl Med 2019; 17: 238.
[5] Martm MG, Lindberg I, Solorzano-Vargas RS, et al. Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort. Gastroenterology 2013; 145: 138-148.
[6] A New Case of PCSK1 Pathogenic Variant With Congenital Proprotein Convertase 1/3 Deficiency and Literature Review - PubMed, https://pubmed.ncbi.nlm.nih.gov/30383237/?from_single_result=30383237&e xpanded_search_query=30383237 (accessed 15 April 2020).
[7] Ganau M, Huet S, Syrmos N, et al. Neuro-Ophthalmological Manifestations Of Septo-Optic Dysplasia: Current Perspectives. Eye Brain 2019; 11: 37-47.
[8] Saranac L, Gucev Z. New insights into septo-optic dysplasia. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2014; 35: 123-127.
[9] Tudor RM, Thompson CJ. Posterior pituitary dysfunction following traumatic brain injury: review. Pituitary 2019; 22: 296-304.
[10] Seckl J, Dunger D. Postoperative diabetes insipidus. BMJ 1989; 298: 2-3.
[11] Hadjizacharia P, Beale EO, Inaba K, et al. Acute diabetes insipidus in severe head injury: a prospective study. J Am Coll Surg 2008; 207: 477-484.
[12] Akinduro OO, Izzo A, Lu VM, et al. Endocrine and Visual Outcomes Following Gross Total Resection and Subtotal Resection of Adult Craniopharyngioma: Systematic Review and Meta-Analysis. World Neurosurg 2019; 127: e656-e668.
[13] Tan TSE, Patel L, Gopal-Kothandapani JS, et al. The neuroendocrine sequelae of paediatric craniopharyngioma: a 40-year meta-data analysis of 185 cases from three UK centres. Eur J Endocrinol 2017; 176: 359-369.
[14] Hoorn EJ, Zietse R. Water balance disorders after neurosurgery: the triphasic response revisited. NDT Plus 2010; 3: 42-44.
[15] Ghirardello S, Hopper N, Albanese A, et al. Diabetes insipidus in craniopharyngioma: postoperative management of water and electrolyte disorders. J Pediatr Endocrinol Metab 2006; 19 Suppl 1: 413-421.
[16] Bichet DG. Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin Nephrol 2008; 28: 245-251.
[17] Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 2005; 16: 2836-2846.
[18] Kozono D, Yasui M, King LS, et al. Aquaporin water channels: atomic structure molecular dynamics meet clinical medicine. J Clin Invest 2002; 109: 1395-1399.
[19] Yamamoto T, Sasaki S. Aquaporins in the kidney: emerging new aspects. Kidney Int 1998; 54: 1041-1051.
[20] Nielsen S, Kwon TH, Christensen BM, et al. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10: 647-663.
[21] BHATIA* MS, GOYAL A, SAHA R, et al. Psychogenic Polydipsia -Management Challenges. Shanghai Arch Psychiatry; 29: 180-183.
[22] Vande Walle J, Stockner M, Raes A, et al. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf 2007; 2: 232-238.
[23] 1-deamino-8-D-arginine Vasopressin in the Treatment of Central Diabetes Insipidus in Childhood - PubMed, https://pubmed.ncbi.nlm.nih.gov/660339/?from_single_result=660339&expan ded_search_query=660339 (accessed 15 April 2020).
[24] Oiso Y, Robertson GL, N0rgaard JP, et al. Clinical review: Treatment of neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 2013; 98: 39583967.
[25] Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985; 103: 228-239.
[26] Mavinkurve M, McGrath N, Johnston N, et al. Oral administration of diluted nasal desmopressin in managing neonatal central diabetes insipidus. J Pediatr EndocrinolMetab 2017; 30: 623-628.
[27] Buccally Administered Intranasal Desmopressin Acetate for the Treatment of Neurogenic Diabetes Insipidus in Infancy - PubMed, https://pubmed.ncbi.nlm.nih.gov/27011115/?from_single_result=27011115&e xpanded_search_query=27011115 (accessed 15 April 2020).
[28] Rivkees SA, Dunbar N, Wilson TA. The management of central diabetes insipidus in infancy: desmopressin, low renal solute load formula, thiazide diuretics. J Pediatr Endocrinol Metab 2007; 20: 459-469.
[29] Blanco EJ, Lane AH, Aijaz N, et al. Use of subcutaneous DDAVP in infants with central diabetes insipidus. J Pediatr Endocrinol Metab 2006; 19: 919-925.